IVX: IVAX Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVX: IVAX Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (64)	4/8/2005 12:41:56 PM
From: Jim Oravetz	Read Replies (1) of 78

FTC Rejects IVAX Claim On Generic Of Merck's Zocor DOW JONES NEWSWIRES April 7, 2005 4:12 p.m. WASHINGTON -- The Federal Trade Commission urged the Food and Drug Administration to reject Ivax Pharmaceuticals Inc.'s (IVX) petition for a 180-day marketing exclusivity period for its generic version of cholesterol drug Zocor. Ivax submitted an abbreviated new drug application for generic Zocor in 2000 and was entitled to exclusivity under two of Merck & Co.'s (MRK) patent claims as mandated by the Hatch-Waxman Act. However, the FDA later removed these two patents from its patent list commonly known as the Orange Book, after determining that they were related to an active ingredient already covered by a separate Merck patent. Ivax's petition requests continuing exclusivity on the generic drug, which the company expects to begin marketing in 2006. An Ivax representative wasn't immediately available to comment on the FTC's response to the petition. The FTC, which has brought a number of patent-related antitrust cases against drug companies, argues that Ivax is mistaken in its characterization of the 180-day exclusivity as a right instead of an incentive to foster competition and to strengthen patents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next